[{"uuid": "2404cefb-6845-3606-a800-b512486f1099", "title": "Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-akero-therapeutics-inc-akro-002552132.html", "providerPublishTime": 1738628752, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/mlJjdy0U1hSdvI3yTxDWOQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/52f642755a03dba96aec7e2253ee8ac5", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ytkuancammRqnFj6nHDfgw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/52f642755a03dba96aec7e2253ee8ac5", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKRO"]}, {"uuid": "5bd4ae72-28a0-337b-8e5d-b53fe0e63538", "title": "Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/akero-therapeutics-inc-akro-among-172821075.html", "providerPublishTime": 1738603701, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/B8nNKitq5.bBLQV_JsrbbA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ac2e6567c554c8e493f33479515309b7", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pZrMaxqKPlqyao24ATHIEQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ac2e6567c554c8e493f33479515309b7", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKRO"]}, {"uuid": "3a47aed7-9416-38ab-abaa-f7719d78b6e7", "title": "Investors Poured $107B Into ETFs in January", "publisher": "etf.com", "link": "https://finance.yahoo.com/m/3a47aed7-9416-38ab-abaa-f7719d78b6e7/investors-poured-%24107b-into.html", "providerPublishTime": 1738626631, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/wXCY_LttPoIzvvK9qphMIQ--~B/aD01OTE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/indexuniverse.com/fe25472506bafc5954db9b754fc8759f", "width": 800, "height": 591, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1V38DuS9aM7_z3oNAAORvA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/indexuniverse.com/fe25472506bafc5954db9b754fc8759f", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "83e8d8f7-d5a3-33fa-b9bc-b1c98d26f5c4", "title": "Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now?", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-akero-therapeutics-akro-among-213525778.html", "providerPublishTime": 1738532125, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/B8nNKitq5.bBLQV_JsrbbA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ac2e6567c554c8e493f33479515309b7", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pZrMaxqKPlqyao24ATHIEQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ac2e6567c554c8e493f33479515309b7", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKRO", "COMP"]}, {"uuid": "a80c8aa6-4515-383f-a6dc-2d57ee22226f", "title": "This Stock Just Doubled in 1 Day -- Is It Still a Buy?", "publisher": "Motley Fool", "link": "https://finance.yahoo.com/m/a80c8aa6-4515-383f-a6dc-2d57ee22226f/this-stock-just-doubled-in-1.html", "providerPublishTime": 1738538460, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/cyMCNq4ZMRsioZV8VFsZbA--~B/aD0xNDE0O3c9MjEyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/b421744cc8f3cd02b1396ca17f5a6773", "width": 2120, "height": 1414, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/kEBEjRmAAzFJncS0hHMHyg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/b421744cc8f3cd02b1396ca17f5a6773", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKRO"]}, {"uuid": "43923322-c542-3c12-a4ba-ff79df1373a1", "title": "UBS Adjusts Price Target on Akero Therapeutics to $109 From $42, Keeps Buy Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/ubs-adjusts-price-target-akero-162307833.html", "providerPublishTime": 1738340587, "type": "STORY", "relatedTickers": ["AKRO"]}, {"uuid": "9e084638-9ae2-3f5e-9fc7-d3a848df2e10", "title": "Akero Therapeutics Insider Sold Shares Worth $2,734,212, According to a Recent SEC Filing", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/akero-therapeutics-insider-sold-shares-141706625.html", "providerPublishTime": 1738333026, "type": "STORY", "relatedTickers": ["AKRO"]}, {"uuid": "fd70ceff-b0ed-3a19-be6d-801ec87880f9", "title": "BNP Paribas Primary New Issues: POST STAB Notice - ENGINEERING INGEGNERIA INFORMATICA S.P.A", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/bnp-paribas-primary-issues-post-090200759.html", "providerPublishTime": 1738314120, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/tffOPE08sW6a2WW_vqZZJQ--~B/aD03Mzt3PTMzNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/c1ba25ef80ff0c284c3576066eb58771", "width": 335, "height": 73, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/N2R7h3QaNTbwn3ymqPshAA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c1ba25ef80ff0c284c3576066eb58771", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "597a082f-c88c-3f98-b729-2a1f46da220f", "title": "Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/akero-therapeutics-announces-closing-upsized-210500897.html", "providerPublishTime": 1738271100, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/VP5zY_hIM6R2ebt8vxENcQ--~B/aD01Nzk7dz0xMDI5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/945f11ed879f0f37ffc89c9186057227", "width": 1029, "height": 579, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/QvT0X777RcRJvAK8zwAz1Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/945f11ed879f0f37ffc89c9186057227", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKRO"]}, {"uuid": "792c0ed4-4157-364d-90fc-a685e38008ac", "title": "BofA Securities Upgrades Akero Therapeutics to Buy, $63 Price Target", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/bofa-securities-upgrades-akero-therapeutics-124547239.html", "providerPublishTime": 1738241147, "type": "STORY", "relatedTickers": ["AKRO"]}, {"uuid": "165bbe34-55f4-3506-8edc-dc9d511d3a8b", "title": "AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/akro-stock-doubles-week-lead-151500816.html", "providerPublishTime": 1738163700, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/rW4gwx51VaA5gxTyv4MLeg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/004265dfd2737a0262868ee5a83c126c", "width": 620, "height": 413, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/z8lneb0ND8JiUY2R3XiQ6g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/004265dfd2737a0262868ee5a83c126c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKRO", "NVO"]}, {"uuid": "afe17d22-d20c-3927-9cfd-3ddbf8007209", "title": "The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-sage-145500682.html", "providerPublishTime": 1738248900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/H5j0X5VJ3peIo6cA0ud3Qg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BIIB", "SAGE", "AKRO", "CYTK"]}, {"uuid": "6640d076-c220-3617-aab9-38b207590a8b", "title": "Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/biotech-stock-roundup-sage-declining-170200168.html", "providerPublishTime": 1738170120, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/GGbbFeHcXoThOctYgnQqXQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["SAGE", "BIIB", "CYTK", "AKRO"]}, {"uuid": "6218e538-80c6-300e-bb5f-bbecf08e7855", "title": "Akero Therapeutics Insider Sold Shares Worth $1,742,958, According to a Recent SEC Filing", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/akero-therapeutics-insider-sold-shares-080911733.html", "providerPublishTime": 1738224551, "type": "STORY", "relatedTickers": ["AKRO"]}, {"uuid": "7f77243a-072b-360e-8809-94b2f5639864", "title": "Akero Therapeutics Insider Sold Shares Worth $1,646,978, According to a Recent SEC Filing", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/akero-therapeutics-insider-sold-shares-080749013.html", "providerPublishTime": 1738224469, "type": "STORY", "relatedTickers": ["AKRO"]}, {"uuid": "9e0c8ea7-9648-3d8c-ac9d-ba58ff93a4a9", "title": "Akero Therapeutics Prices $350 Million Upsized Public Offering", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/akero-therapeutics-prices-350-million-093724316.html", "providerPublishTime": 1738143444, "type": "STORY", "relatedTickers": ["AKRO"]}, {"uuid": "8c32abf7-54b9-3cb6-b0b0-cc3d24e4cac6", "title": "Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/akero-therapeutics-announces-pricing-upsized-023000756.html", "providerPublishTime": 1738117800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/VP5zY_hIM6R2ebt8vxENcQ--~B/aD01Nzk7dz0xMDI5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/945f11ed879f0f37ffc89c9186057227", "width": 1029, "height": 579, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/QvT0X777RcRJvAK8zwAz1Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/945f11ed879f0f37ffc89c9186057227", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKRO"]}, {"uuid": "e19f0f68-5315-3727-bc87-aadbc29a3bdc", "title": "Why Akero Therapeutics Inc. (AKRO) Surged on Monday", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-akero-therapeutics-inc-akro-134058408.html", "providerPublishTime": 1738071658, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/B8nNKitq5.bBLQV_JsrbbA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ac2e6567c554c8e493f33479515309b7", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pZrMaxqKPlqyao24ATHIEQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ac2e6567c554c8e493f33479515309b7", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKRO", "^GSPC"]}, {"uuid": "d7eb9aae-af7d-3cff-84d9-803356133462", "title": "Stabilization Notice - Pre STAB Engineering EUR Fix & FRN", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/stabilization-notice-pre-stab-engineering-094500233.html", "providerPublishTime": 1738143900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/tffOPE08sW6a2WW_vqZZJQ--~B/aD03Mzt3PTMzNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/c1ba25ef80ff0c284c3576066eb58771", "width": 335, "height": 73, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/N2R7h3QaNTbwn3ymqPshAA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c1ba25ef80ff0c284c3576066eb58771", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "e64384cb-61ef-3fde-86f7-0be3c6ea7f84", "title": "BioAge drops obesity drug; Akero, 89bio cash in on MASH data", "publisher": "BioPharma Dive", "link": "https://finance.yahoo.com/m/e64384cb-61ef-3fde-86f7-0be3c6ea7f84/bioage-drops-obesity-drug%3B.html", "providerPublishTime": 1738147185, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/H45ciFL01k8pIJfsr8ZYEA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259", "width": 1600, "height": 900, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/m8gMMn1cTlFUNNLyoWoNVA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BIOA", "AKRO", "VNDA", "ALLK"]}]